Robeco Institutional Asset Management B.V. Boosts Stake in Zimmer Biomet Holdings Inc (ZBH)

Robeco Institutional Asset Management B.V. lifted its position in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) by 113.2% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 5,120 shares of the medical equipment provider’s stock after acquiring an additional 2,718 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Zimmer Biomet were worth $618,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of ZBH. Longview Partners Guernsey LTD increased its position in shares of Zimmer Biomet by 17.7% in the third quarter. Longview Partners Guernsey LTD now owns 7,506,684 shares of the medical equipment provider’s stock worth $878,958,000 after purchasing an additional 1,128,973 shares during the period. Koch Industries Inc. increased its position in shares of Zimmer Biomet by 49,697.3% in the second quarter. Koch Industries Inc. now owns 1,040,764 shares of the medical equipment provider’s stock worth $1,033,000 after purchasing an additional 1,038,674 shares during the period. Alyeska Investment Group L.P. increased its position in shares of Zimmer Biomet by 249.3% in the third quarter. Alyeska Investment Group L.P. now owns 1,019,872 shares of the medical equipment provider’s stock worth $119,417,000 after purchasing an additional 727,925 shares during the period. Jana Partners LLC increased its position in shares of Zimmer Biomet by 16.6% in the third quarter. Jana Partners LLC now owns 4,662,497 shares of the medical equipment provider’s stock worth $545,932,000 after purchasing an additional 662,497 shares during the period. Finally, Bank of New York Mellon Corp increased its position in shares of Zimmer Biomet by 24.4% in the third quarter. Bank of New York Mellon Corp now owns 2,759,704 shares of the medical equipment provider’s stock worth $323,134,000 after purchasing an additional 541,102 shares during the period. 86.18% of the stock is owned by institutional investors.

A number of brokerages recently commented on ZBH. Goldman Sachs Group upgraded Zimmer Biomet from a “sell” rating to a “neutral” rating and set a $125.00 price target on the stock in a research report on Tuesday, December 19th. Stifel Nicolaus upgraded Zimmer Biomet from a “hold” rating to a “buy” rating and raised their price target for the stock from $120.00 to $168.00 in a research report on Wednesday, January 31st. Canaccord Genuity restated a “hold” rating and issued a $132.00 price target on shares of Zimmer Biomet in a research report on Friday, January 5th. Robert W. Baird restated a “buy” rating on shares of Zimmer Biomet in a research report on Wednesday, January 31st. Finally, BMO Capital Markets restated a “buy” rating and issued a $142.00 price target on shares of Zimmer Biomet in a research report on Tuesday, December 12th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $141.67.

Zimmer Biomet Holdings Inc (NYSE:ZBH) opened at $120.78 on Thursday. Zimmer Biomet Holdings Inc has a 12-month low of $108.03 and a 12-month high of $133.49. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.52 and a quick ratio of 0.83. The stock has a market capitalization of $24,940.64, a PE ratio of 13.41, a price-to-earnings-growth ratio of 2.16 and a beta of 1.08.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Tuesday, January 30th. The medical equipment provider reported $2.10 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $2.10. The firm had revenue of $2.07 billion for the quarter, compared to analysts’ expectations of $2.03 billion. Zimmer Biomet had a return on equity of 15.45% and a net margin of 23.51%. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.14 earnings per share. equities research analysts forecast that Zimmer Biomet Holdings Inc will post 7.82 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Monday, January 29th. Stockholders of record on Friday, December 29th were issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.79%. The ex-dividend date of this dividend was Thursday, December 28th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 10.65%.

TRADEMARK VIOLATION WARNING: This report was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.com-unik.info/2018/02/08/robeco-institutional-asset-management-b-v-boosts-stake-in-zimmer-biomet-holdings-inc-zbh.html.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit